Route of administration, dosing strategy, and treatment sequence can also vary depending on the patients age, baseline status, medical history, and comorbidities
It can be administered in two forms: Oral tablets (Rybelsus): Has been shown to improve glycemic control in people with type 2 diabetes mellitus
The DECLARE, CANVAS and EMPA-REG CV outcomes trials assessing the SGLT2 inhibitors dapagliflozin (Farxiga, AstraZeneca), canagliflozin (Invokana, Janssen) and empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), respectively, all showed CV and renal benefit in adults with type 2 diabetes with established CVD, DeFronzo said
Consumers, of course, get the best of both worldssafe, effective medicine for less than the list price